{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T10:07:44Z","timestamp":1742638064676},"reference-count":23,"publisher":"FapUNIFESP (SciELO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Gastroenterol."],"published-print":{"date-parts":[[2015,9]]},"abstract":"<jats:p>BackgroundTreatment of hepatitis C virus infection in post-transplantation patients is a challenge due to poor tolerance and low success rates.ObjectiveTo determine the response rate to pegylated interferon and ribavirin in post-liver transplant patients with hepatitis C recurrence.MethodsBetween 18 May 2002 and 18 December 2011, 601 patients underwent liver transplantation at our service (Hospital Universit\u00e1rio Walter Cant\u00eddio, University of Cear\u00e1), 176 (29.2%) of whom were hepatitis C virus positive. Forty received antiviral therapy and were included in this cohort study. Twenty-eight (70%) completed the treatment protocol, which consisted of pegylated interferon and ribavirin for 48 weeks.ResultsThe sustained virological response rate was 55% according to intention-to-treat analysis. Recipient age and exposure to antiviral drugs prior to liver transplantation were associated with sustained virological response in the multivariate analysis. Patients were followed for 57 months on the average. Survival at 1 and 5 years was 100% in responders, versus 100% and 78%, respectively, in non-responders.ConclusionSustained virological response rates were satisfactory in our series of liver transplantation patients, and decreased with increasing recipient age. Non-exposure to antiviral drugs prior to liver transplantation was positively associated with sustained virological response. The overall survival of responders and non-responders was similar.<\/jats:p>","DOI":"10.1590\/s0004-28032015000300012","type":"journal-article","created":{"date-parts":[[2015,10,15]],"date-time":"2015-10-15T13:06:45Z","timestamp":1444914405000},"page":"216-221","source":"Crossref","is-referenced-by-count":2,"title":["PEGYLATED INTERFERON AND RIBAVIRIN FOR TREATMENT OF RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION: a single-liver transplant center experience in Brazil"],"prefix":"10.1590","volume":"52","author":[{"given":"Jos\u00e9 Huygens Parente","family":"GARCIA","sequence":"first","affiliation":[{"name":"Universidade Federal do Cear\u00e1,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ant\u00f4nio Haroldo de","family":"ARA\u00daJO FILHO","sequence":"additional","affiliation":[{"name":"Hospital Universit\u00e1rio Walter Cant\u00eddio,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia Libanez Bessa Campelo","family":"BRAGA","sequence":"additional","affiliation":[{"name":"Universidade Federal do Cear\u00e1,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyntia Ferreira Gomes","family":"VIANA","sequence":"additional","affiliation":[{"name":"Hospital Universit\u00e1rio Walter Cant\u00eddio,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarciso Daniel Santos","family":"ROCHA","sequence":"additional","affiliation":[{"name":"Hospital Universit\u00e1rio Walter Cant\u00eddio,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karla Brand\u00e3o","family":"PEREIRA","sequence":"additional","affiliation":[{"name":"Hospital Universit\u00e1rio Walter Cant\u00eddio,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"key":"ref1","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/686135","article-title":"Liver transplantation and hepatitis C","volume":"2012","author":"Akamatsu N","year":"2012","journal-title":"Int J Hepatol"},{"issue":"3","key":"ref2","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.transproceed.2009.02.006","article-title":"Treatment for recurrent hepatitis C virus infection after liver transplantation","volume":"41","author":"Balbi E","year":"2009","journal-title":"Transplant Proc"},{"issue":"7","key":"ref3","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/lt.20737","article-title":"Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C","volume":"12","author":"Berenguer M","year":"2006","journal-title":"Liver Transpl"},{"issue":"2","key":"ref4","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jhep.2008.05.002","article-title":"Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with Ribavirina","volume":"49","author":"Berenguer M","year":"2008","journal-title":"J Hepatol"},{"issue":"4","key":"ref5","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.cld.2005.08.004","article-title":"Treatment of hepatitis C after liver transplantation","volume":"9","author":"Berenguer M","year":"2005","journal-title":"Clin Liver Diseases"},{"issue":"5","key":"ref6","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.jhep.2010.06.006","article-title":"Retransplantation in patients with hepatitis C recurrence after liver transplantation","volume":"53","author":"Carri\u00f3n JA","year":"2010","journal-title":"J Hepatol"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1053\/j.gastro.2014.10.001","article-title":"Sofosbuvir and Ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation","volume":"148","author":"Charlton M","year":"2015","journal-title":"Gastroenterology"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/liv.12062","article-title":"Current management and perspectives for HCV recurrence after liver transplantation","volume":"33","author":"Coilly A","year":"2013","journal-title":"Liver Int"},{"issue":"6","key":"ref9","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1097\/00000658-199906000-00009","article-title":"Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during 8-year sigle-center experience","volume":"229","author":"Ghobrial RM","year":"1999","journal-title":"Ann Surg"},{"issue":"10","key":"ref10","first-page":"637","article-title":"Management of recurrent hepatitis C following liver transplantation","volume":"6","author":"Gonzalez SA","year":"2010","journal-title":"Gastroenterol Hepatol"},{"issue":"2","key":"ref11","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1365-2036.2010.04505.x","article-title":"Systematic review: anti-viral therapy of recurrent hepatitis C after liver transplantation","volume":"33","author":"Guillouche P","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"ref12","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1399-0012.2009.00961.x","article-title":"Response to antiviral therapy in liver transplant recipients with recurrent hepatitis C viral infection: a single center experience","volume":"24","author":"Jain A","year":"2010","journal-title":"Clin Transplant"},{"issue":"5","key":"ref13","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1002\/hep.25653","article-title":"Review and management of drug interactions with boceprevir and telaprevir","volume":"55","author":"Kiser JJ","year":"2012","journal-title":"Hepatology"},{"issue":"2","key":"ref14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1469-0691.2010.03432.x","article-title":"Evolving epidemiology of hepatitis C virus","volume":"17","author":"Lavanchy D","year":"2011","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"ref15","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"68","author":"Lawitz E","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"ref16","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1053\/j.gastro.2008.02.028","article-title":"Indications for liver transplantation","volume":"134","author":"O\u2019Leary JG","year":"2008","journal-title":"Gastroenterology"},{"issue":"2","key":"ref17","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1023\/A:1013759230800","article-title":"Outcome of orthotopic liver transplantation in patients with hepatitis C","volume":"47","author":"Paik SW","year":"2002","journal-title":"Dig Dis Sci"},{"issue":"3","key":"ref18","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jhep.2006.10.017","article-title":"Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation","volume":"46","author":"Picciotto FP","year":"2007","journal-title":"J Hepatol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jhep.2006.05.001","article-title":"Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14,2006)","volume":"45","author":"Samuel D","year":"2006","journal-title":"J Hepatol"},{"issue":"7","key":"ref20","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s10620-009-0982-2","article-title":"Antiviral treatment of patients with recurrent hepatitis C after liver transplantation with pegylated interferon","volume":"55","author":"Schmidt SC","year":"2010","journal-title":"Dig. Dis. Sci"},{"issue":"10","key":"ref21","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1097\/TP.0b013e3181bd783c","article-title":"Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome","volume":"88","author":"Selzner N","year":"2009","journal-title":"Transplantation"},{"issue":"4","key":"ref22","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/j.1600-6143.2011.03899.x","article-title":"Liver transplantation for hepatitis C from donation after cardiac death donors: An analysis of OPTN\/UNOS data","volume":"12","author":"Uemura T","year":"2012","journal-title":"Am J Transplant"},{"issue":"7","key":"ref23","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/j.1600-6143.2006.01362.x","article-title":"Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis","volume":"6","author":"Wang CS","year":"2006","journal-title":"Am J Transplant"}],"container-title":["Arquivos de Gastroenterologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/ag\/v52n3\/0004-2803-ag-52-03-216.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T01:53:45Z","timestamp":1495504425000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-28032015000300216&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0004-28032015000300216"],"URL":"https:\/\/doi.org\/10.1590\/s0004-28032015000300012","relation":{},"ISSN":["0004-2803"],"issn-type":[{"value":"0004-2803","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9]]}}}